6-K 1 f6k110818_xtlbiopharma.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of November, 2018

Commission File Number: 001-36000

XTL Biopharmaceuticals Ltd.

(Translation of registrant’s name into English)

5 Badner St.

Ramat Gan,
4365603, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

The management of XTL Biopharmaceuticals Ltd. will be presenting at an investor conference on November 11, 2018. A copy of the presentation is furnished as Exhibit 99.1 to this Report on Form 6-K.

| 1 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| XTL BIOPHARMACEUTICALS LTD.
Date: November 8, 2018 | By: | /s/ Josh Levine
|  | Josh Levine
|  | Chief Executive Officer

| 2 |

Exhibit Index

Exhibit Number |  | Exhibit Title
99.1 |  | XTL Biopharmaceuticals Ltd. Investor Presentation

| 3 |